T CELL RECEPTORS RECOGNIZING HLA-A1-RESTRICTED MAGE-A3
US Patent 12,441,778
Filed on 2022-03-10
Filed on 2022-03-10
Intracellular Genomic Transplant and Methods of Therapy
US Application 17/674,378
Filed on 2022-02-17
Filed on 2022-02-17
Intermittent Dosing Of Cediranib Alone Or In Combination With Durvalumab
US Application 16/077,720
Filed on 2018-08-13
Filed on 2018-08-13
Intermittent Dosing Of Cediranib Alone Or In Combination With Durvalumab
Russia
2018131377
Filed on 2017-02-14
2018131377
Filed on 2017-02-14
Intermittent Dosing Of Cediranib Alone Or In Combination With Durvalumab
Mexico
2018009867
Filed on 2017-02-14
2018009867
Filed on 2017-02-14
Intermittent Dosing Of Cediranib Alone Or In Combination With Durvalumab
Morocco
17753704.0
Filed on 2017-02-14
17753704.0
Filed on 2017-02-14
METHODS COMPRISING FIXED INTERMITTENT DOSING OF CEDIRANIB
South Korea
10-2018-7024215
Filed on 2017-02-14
10-2018-7024215
Filed on 2017-02-14
Intermittent Dosing Of Cediranib Alone Or In Combination With Durvalumab
Japan
2021-064539
Filed on 2021-04-06
2021-064539
Filed on 2021-04-06
Intermittent Dosing Of Cediranib Alone Or In Combination With Durvalumab
European Patent
17753704.0
Filed on 2017-02-14
17753704.0
Filed on 2017-02-14
Intermittent Dosing Of Cediranib Alone Or In Combination With Durvalumab
China
201780011505.X
Filed on 2017-02-14
201780011505.X
Filed on 2017-02-14